Relief of pain induced by irritable bowel syndrome

Otilonium bromide is the prototype of a class of 2-aminoethyl-N-benzoylamino-benzoate quaternary salts, which exert selective interference with the mobilization of calcium ions intra- and extracellular of intestinal myocytes, competitively suppress and inhibit muscarinic M2 receptors and tachtykininNK2 receptors. It also has a powerful selective antispasmodic action on the smooth muscle of the digestive tract, particularly in the colon, at doses which do not affect gastric secretion or produce typical atropine-like adverse effects

Poorly absorbed from the gastrointestinal tract, Bioavailability＜3%, High distribution in the colon smooth muscle; Excretion: 97.1% by feces as unchanged form, 0.71% by urine.

Hypersensitivity to otilonium bromide, the drug should used with caution in patients with glaucoma, prostatic hypertrophy and pyloric stenosis.

No reports of embryotoxicity, teratogenic or mutagenic effects in animals, it should be given to pregnant women and nursing mothers if absolutely necessary and under close medical supervision.

Unknown

nausea, vomiting, epigastric pain, abdominal discomfort, vertigo, headache

40 mg orally BID∼TID